XM does not provide services to residents of the United States of America.
A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Roche CEO: breast cancer pill could enter $12 bln market if trials succeed

UPDATE 1-Roche CEO: breast cancer pill could enter $12 bln market if trials succeed Adds background from paragraph 2 By Ludwig Burger MANNHEIM, Germany, Oct 9 (Reuters) - Roche's ROG.S experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion) a year if it clears two key trials on early treatment of the disease, the Swiss drugmaker's CEO said.
A
R
S

US natgas prices ease 1% to 1-week low ahead of Hurricane Milton

UPDATE 1-US natgas prices ease 1% to 1-week low ahead of Hurricane Milton Adds latest prices By Scott DiSavino Oct 8 (Reuters) - U.S. natural gas futures eased about 1% to a fresh one-week low on Tuesday on expectations power generators would burn less gas after Hurricane Milton knocks out power to potentially millions of homes and businesses in Florida later this week.
A
N

US natgas prices hold near 1-week low ahead of Hurricane Milton

US natgas prices hold near 1-week low ahead of Hurricane Milton By Scott DiSavino Oct 8 (Reuters) - U.S. natural gas futures held near a one-week low on Tuesday as lower output and higher demand forecasts offset expectations Hurricane Milton could cause millions of homes and businesses to lose power in Florida later this week. Those power outages will reduce the amount of gas generators need to burn - possibly for days.
A
N

British Business - Oct 8

PRESS DIGEST-British Business - Oct 8 Oct 8 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - AstraZeneca AZN.L has entered into the exclusive deal with CSPC Pharmaceutical Group 1093.HK potentially worth up to $2 billion to develop an experimental drug to tackle unhealthy cholesterol levels and related cardiovascular diseases.
A
B
J
R

Cboe to list hedged ADRs developed by Precidian

Cboe to list hedged ADRs developed by Precidian By Laura Matthews NEW YORK, Oct 7 (Reuters) - Precidian Investments launched hedged ADRs on Monday that U.S. investors can use to buy foreign-listed stocks while limiting the impact of fluctuating currencies. Precidian, an exchange-traded fund developer, said it will list the hedged American Depositary Receipts on Cboe's U.S.
A
H
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.